| 臺大學術典藏 |
2022-01-24T09:32:03Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
CHUN-JEN LIU; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2022-01-24T09:31:38Z |
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence
|
CHUN-JEN LIU; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2022-01-11T06:49:24Z |
Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study
|
HSIEN-YI CHIU; Chiu Y.-M.; Chang Liao N.-F.; Chi C.-C.; Tsai T.-F.; Hsieh C.-Y.; Hsieh T.-Y.; Lai K.-L.; Chiu T.-M.; Wu N.-L.; Hui R.C.-Y.; Lee C.-N.; Wang T.-S.; Chen P.-H.; Yang C.-C.; Huang Y.-H. |
| 國立成功大學 |
2022 |
Most bothersome symptoms in patients with migraine: A hospital-based study in Taiwan
|
Tu, Y.-H.;Wang, Y.-F.;Yuan, H.;Chen, S.-P.;Tzeng, Y.-S.;Chen, W.-T.;Lai, K.-L.;Ling, Y.-H.;Wang, S.-J. |
| 臺大學術典藏 |
2021-10-28T07:11:16Z |
Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study
|
Chiu H.-Y.; Chiu Y.-M.; Chang Liao N.-F.; Chi C.-C.; TSEN-FANG TSAI; Hsieh C.-Y.; Hsieh T.-Y.; Lai K.-L.; Chiu T.-M.; Wu N.-L.; Hui R.C.-Y.; Lee C.-N.; Wang T.-S.; Chen P.-H.; Yang C.-C.; Huang Y.-H. |
| 臺大學術典藏 |
2021-08-16T08:36:14Z |
The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial
|
ARISTINE CHENG; Hsieh S.-M.; Pan S.-C.; Li Y.-H.; Hsieh E.-F.; Lee H.-C.; Lin T.-W.; Lai K.-L.; Chen C.; Shi-Chung Chang S.; Chang S.-C. |
| 臺大學術典藏 |
2021-07-03T03:34:53Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
Liu C.-J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; PEI-JER CHEN |
| 臺大學術典藏 |
2021-07-03T03:34:06Z |
Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence
|
Liu C.-J.; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; PEI-JER CHEN |
| 國立成功大學 |
2021 |
Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study
|
Chiu, H.-Y.;Chiu, Y.-M.;Chang, Liao N.-F.;Chi, Chi C.-C.;Tsai, Tsai T.-F.;Hsieh, C.-Y.;Hsieh, T.-Y.;Lai, K.-L.;Chiu, T.-M.;Wu, N.-L.;Hui, R.C.-Y.;Lee, C.-N.;Wang, T.-S.;Chen, P.-H.;Yang, C.-C.;Huang, Y.-H. |
| 臺大學術典藏 |
2020-12-30T02:44:11Z |
The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial
|
Cheng A.; Hsieh S.-M.; Pan S.-C.; Li Y.-H.; Hsieh E.-F.; Lee H.-C.; Lin T.-W.; Lai K.-L.; Chen C.; Shi-Chung Chang S.; SHAN-CHWEN CHANG |
